Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma

Tae Sung Kim, W. S. Xu, T. Sun, E. P. Cohen

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

LM mouse fibroblasts (H-2(k)) were modified for the expression of (antibody-defined) melanoma-associated antigens (MAA) and the secretion of Interieukin-2 (IL-2) and interferon-gamma (IFN-γ) (RLBA-IL-2/IFN-γ cells). The cell construct was tested for Its immunogenic properties in C57BL/6 mice (H-2b) with B16 melanoma. The results Indicated that the survival of mice injected with a mixture of B16 cells and the modified, double cytokine-secreting fibroblasts was significantly longer than that of mice injected with B16 cells and LM cells modified for the expression of MAA and the secretion of IL-2 or IFN-γ alone (RLBA-IL-2 or RLBA-IFN-γ cells). Both natural killer/ lymphokine activated killer (NK/LAK) cells and Lyt-2.2+CTLs with anti-melanoma cytotoxic activities were predominant in mice immunized with the double cytokine-secreting cells. B16 melanoma cells persisted in mice treated with RLBA-IL-2 cells (B16-R3). The B16-R3 cells were resistant to anti-melanoma effector cells from mice immunized with RLBA-IL-2 cells. The recurrent melanoma cells were deficient in the expression of MHC class I determinants. Class I expression by B16-R3 cells was Increased If they were Incubated in medium conditioned by the growth of IFN-γ-secreting RLBA-lL-2/IFN-γ or RLBA-IFN-cells. After Incubation, the sensitivity of B16-R3 melanoma cells to Immune-effector cells from mice immunized with RLBA-IL-2 cells was restored. The survival of mice bearing low MHC class I-expressing B16-R3 cells, treated RLBA-IL-2/IFN-γ cells, was determined. The treated animals survived significantly longer than mice with B16-R3 melanoma treated with RLBA-IL-2 cells. Similar results were obtained for mice with B16-R3 melanoma treated with RLBA-IFN-γ cells. We postulate that Immunization of mice with IL-2/IFN-γ double cytokine-secreting cells stimulated multiple anti-melanoma effector mechanisms. Analogous to the enhanced therapeutic antitumour effects of combination chemotherapy, it was likely that treatment with a cellular Immunogen engineered to stimulate more than one effector mechanism resulted in the elimination of larger numbers of tumour cells than treatment with an immunogen that stimulated a single effector mechanism alone.

Original languageEnglish
Pages (from-to)217-227
Number of pages11
JournalMelanoma Research
Volume5
Issue number4
Publication statusPublished - 1995 Jul 26
Externally publishedYes

Fingerprint

Interferons
Interleukin-2
Melanoma
Immunization
Fibroblasts
Cytokines
Interferon-gamma
Experimental Melanomas
Melanoma-Specific Antigens
Lymphokine-Activated Killer Cells
Therapeutic Uses

Keywords

  • Allogeneic MHC
  • B16 melanoma
  • Gene therapy
  • Interferon-γ
  • Interleukin-2

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Cite this

Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. / Kim, Tae Sung; Xu, W. S.; Sun, T.; Cohen, E. P.

In: Melanoma Research, Vol. 5, No. 4, 26.07.1995, p. 217-227.

Research output: Contribution to journalArticle

@article{d3b3c6fda20149a580c1c52f8d626bc7,
title = "Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma",
abstract = "LM mouse fibroblasts (H-2(k)) were modified for the expression of (antibody-defined) melanoma-associated antigens (MAA) and the secretion of Interieukin-2 (IL-2) and interferon-gamma (IFN-γ) (RLBA-IL-2/IFN-γ cells). The cell construct was tested for Its immunogenic properties in C57BL/6 mice (H-2b) with B16 melanoma. The results Indicated that the survival of mice injected with a mixture of B16 cells and the modified, double cytokine-secreting fibroblasts was significantly longer than that of mice injected with B16 cells and LM cells modified for the expression of MAA and the secretion of IL-2 or IFN-γ alone (RLBA-IL-2 or RLBA-IFN-γ cells). Both natural killer/ lymphokine activated killer (NK/LAK) cells and Lyt-2.2+CTLs with anti-melanoma cytotoxic activities were predominant in mice immunized with the double cytokine-secreting cells. B16 melanoma cells persisted in mice treated with RLBA-IL-2 cells (B16-R3). The B16-R3 cells were resistant to anti-melanoma effector cells from mice immunized with RLBA-IL-2 cells. The recurrent melanoma cells were deficient in the expression of MHC class I determinants. Class I expression by B16-R3 cells was Increased If they were Incubated in medium conditioned by the growth of IFN-γ-secreting RLBA-lL-2/IFN-γ or RLBA-IFN-cells. After Incubation, the sensitivity of B16-R3 melanoma cells to Immune-effector cells from mice immunized with RLBA-IL-2 cells was restored. The survival of mice bearing low MHC class I-expressing B16-R3 cells, treated RLBA-IL-2/IFN-γ cells, was determined. The treated animals survived significantly longer than mice with B16-R3 melanoma treated with RLBA-IL-2 cells. Similar results were obtained for mice with B16-R3 melanoma treated with RLBA-IFN-γ cells. We postulate that Immunization of mice with IL-2/IFN-γ double cytokine-secreting cells stimulated multiple anti-melanoma effector mechanisms. Analogous to the enhanced therapeutic antitumour effects of combination chemotherapy, it was likely that treatment with a cellular Immunogen engineered to stimulate more than one effector mechanism resulted in the elimination of larger numbers of tumour cells than treatment with an immunogen that stimulated a single effector mechanism alone.",
keywords = "Allogeneic MHC, B16 melanoma, Gene therapy, Interferon-γ, Interleukin-2",
author = "Kim, {Tae Sung} and Xu, {W. S.} and T. Sun and Cohen, {E. P.}",
year = "1995",
month = "7",
day = "26",
language = "English",
volume = "5",
pages = "217--227",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma

AU - Kim, Tae Sung

AU - Xu, W. S.

AU - Sun, T.

AU - Cohen, E. P.

PY - 1995/7/26

Y1 - 1995/7/26

N2 - LM mouse fibroblasts (H-2(k)) were modified for the expression of (antibody-defined) melanoma-associated antigens (MAA) and the secretion of Interieukin-2 (IL-2) and interferon-gamma (IFN-γ) (RLBA-IL-2/IFN-γ cells). The cell construct was tested for Its immunogenic properties in C57BL/6 mice (H-2b) with B16 melanoma. The results Indicated that the survival of mice injected with a mixture of B16 cells and the modified, double cytokine-secreting fibroblasts was significantly longer than that of mice injected with B16 cells and LM cells modified for the expression of MAA and the secretion of IL-2 or IFN-γ alone (RLBA-IL-2 or RLBA-IFN-γ cells). Both natural killer/ lymphokine activated killer (NK/LAK) cells and Lyt-2.2+CTLs with anti-melanoma cytotoxic activities were predominant in mice immunized with the double cytokine-secreting cells. B16 melanoma cells persisted in mice treated with RLBA-IL-2 cells (B16-R3). The B16-R3 cells were resistant to anti-melanoma effector cells from mice immunized with RLBA-IL-2 cells. The recurrent melanoma cells were deficient in the expression of MHC class I determinants. Class I expression by B16-R3 cells was Increased If they were Incubated in medium conditioned by the growth of IFN-γ-secreting RLBA-lL-2/IFN-γ or RLBA-IFN-cells. After Incubation, the sensitivity of B16-R3 melanoma cells to Immune-effector cells from mice immunized with RLBA-IL-2 cells was restored. The survival of mice bearing low MHC class I-expressing B16-R3 cells, treated RLBA-IL-2/IFN-γ cells, was determined. The treated animals survived significantly longer than mice with B16-R3 melanoma treated with RLBA-IL-2 cells. Similar results were obtained for mice with B16-R3 melanoma treated with RLBA-IFN-γ cells. We postulate that Immunization of mice with IL-2/IFN-γ double cytokine-secreting cells stimulated multiple anti-melanoma effector mechanisms. Analogous to the enhanced therapeutic antitumour effects of combination chemotherapy, it was likely that treatment with a cellular Immunogen engineered to stimulate more than one effector mechanism resulted in the elimination of larger numbers of tumour cells than treatment with an immunogen that stimulated a single effector mechanism alone.

AB - LM mouse fibroblasts (H-2(k)) were modified for the expression of (antibody-defined) melanoma-associated antigens (MAA) and the secretion of Interieukin-2 (IL-2) and interferon-gamma (IFN-γ) (RLBA-IL-2/IFN-γ cells). The cell construct was tested for Its immunogenic properties in C57BL/6 mice (H-2b) with B16 melanoma. The results Indicated that the survival of mice injected with a mixture of B16 cells and the modified, double cytokine-secreting fibroblasts was significantly longer than that of mice injected with B16 cells and LM cells modified for the expression of MAA and the secretion of IL-2 or IFN-γ alone (RLBA-IL-2 or RLBA-IFN-γ cells). Both natural killer/ lymphokine activated killer (NK/LAK) cells and Lyt-2.2+CTLs with anti-melanoma cytotoxic activities were predominant in mice immunized with the double cytokine-secreting cells. B16 melanoma cells persisted in mice treated with RLBA-IL-2 cells (B16-R3). The B16-R3 cells were resistant to anti-melanoma effector cells from mice immunized with RLBA-IL-2 cells. The recurrent melanoma cells were deficient in the expression of MHC class I determinants. Class I expression by B16-R3 cells was Increased If they were Incubated in medium conditioned by the growth of IFN-γ-secreting RLBA-lL-2/IFN-γ or RLBA-IFN-cells. After Incubation, the sensitivity of B16-R3 melanoma cells to Immune-effector cells from mice immunized with RLBA-IL-2 cells was restored. The survival of mice bearing low MHC class I-expressing B16-R3 cells, treated RLBA-IL-2/IFN-γ cells, was determined. The treated animals survived significantly longer than mice with B16-R3 melanoma treated with RLBA-IL-2 cells. Similar results were obtained for mice with B16-R3 melanoma treated with RLBA-IFN-γ cells. We postulate that Immunization of mice with IL-2/IFN-γ double cytokine-secreting cells stimulated multiple anti-melanoma effector mechanisms. Analogous to the enhanced therapeutic antitumour effects of combination chemotherapy, it was likely that treatment with a cellular Immunogen engineered to stimulate more than one effector mechanism resulted in the elimination of larger numbers of tumour cells than treatment with an immunogen that stimulated a single effector mechanism alone.

KW - Allogeneic MHC

KW - B16 melanoma

KW - Gene therapy

KW - Interferon-γ

KW - Interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=0028981435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028981435&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 217

EP - 227

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 4

ER -